MIF-1 (Pro-Leu-Gly-NH₂)
Research chemical · Grade C
Evidence
0 RCT / 4 animal / 2 in vitro
Routes
injectable-sc, nasal, oral
Half-life
The dosing frequency for MIF-1 based on this half-life would theoretically be very low — perhaps once every 2-5 days rather than daily
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
Pinealon
Bioregulator · Grade C
Goals
cognition, sleep, longevity
Evidence
0 RCT / 1 animal / 2 in vitro
Routes
injectable-sc, injectable-im
Typical dose
Community protocols commonly cite 2 mg daily for 10 days; evidence is extrapolated
Half-life
Unknown in humans; short peptide, likely rapid systemic clearance
Primary mechanism
Direct chromatin-interaction hypothesis
DSIP
Research chemical · Grade C
Evidence
1 RCT / 6 animal / 1 in vitro
Routes
injectable-sc, nasal
Half-life
In animal studies: the half-life appears even shorter — approximately 4-5 minutes in vivo
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.